Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. (Q45970934)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

Hein J Bernelot Moens

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Alfons A den Broeder

object named as

Alfons A den Broeder

4

0 references

author name string

Wietske Kievit

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Jaap Fransen

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Eddy M M Adang

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Henk Visser

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Mart A F van de Laar

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Piet L C M van Riel

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

publication date

14 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

50

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

196-203

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

The need for randomization in the study of intended effects.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

European biologicals registers: methodology, selected results and perspectives

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

The MOS 36-ltem Short-Form Health Survey (SF-36)

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

[Dose adjustment in patients treated with infliximab in routine rheumatologic care in Germany. Results from the Biologics Register RABBIT].

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Methods to assess intended effects of drug treatment in observational studies are reviewed

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

The central role of the propensity score in observational studies for causal effects

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Explanatory and pragmatic attitudes in therapeutical trials

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Anti-TNF-alpha agents are less effective for the treatment of rheumatoid arthritis in current smokers

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Quality of life and costs for different treatment strategies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Re: Wolfe et al. Do rheumatology cost-effectiveness analyses make sense?

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEQ325

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KEQ325

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21078625

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45970934&oldid=1260345883"